Clinical Trials/Medical Resources: Infinity Pharmaceuticals Initiates Phase I Clinical Trial of IPI-504 for Patients with Gastrointestinal Stromal Tumors (GIST) [Read More] Glivec International Patient Assistance Program (GIPAP) can help defray the cost of Gleevec. [Read More] Novartis (Gleevec) Patient Assistance Program also helps with the cost of obtaining Gleevec. 1-866-884-5906 Pfizer Oncology's FIRSTresource program, can help defray the cost of accessing the newly approved drug, SUTENT. (patient brochure) AMN107, under development by Novartis, which also makes Gleevec, is one of two "son of Gleevec" agents being pursued to treat patients who are refractory to Gleevec or who develop resistance.[Read More] Help Novartis Oncology collect information from doctors on the diagnosis and management of GIST via doctor participation in a GIST registry. A copy of a brochure about the GIST registry is available for you to print and then bring to your doctor by clicking here. ASCO's information for people living with cancer. [Link]

Education/Research Resources: The Internet Guide to GIST Resources   Click here to download this guide.  It installs the information on your computer so that you have the information at your fingertips when ever you need it.  Note: You may get a pop-up blocker, just allow the pop-ups.  If yor are asked to download ActiveX, you need to do that too.  It may seem like a little trouble but once it is installed on your computer you will find it to be  invaluable and a big time saver.  If you have need help please contact: Bill@GISTinfo.org . Archive: Kinasedx.com GIST Information Resource Page and Presentation  Heinrich-Corless Laboratory ASCO 2006 Presentation: Improved survival and sustained clinical benefit with SU11248 (SU) in pts with GIST after failure of imatinib mesylate therapy in a phase III trial, 2006. [ASCO Website] ASCO 2006 Presentation: Outcome of advanced GIST patients treated with imatinib mesylate: four-year follow-up of a randomized Phase II trial [ASCO Website} ASCO 2005 Presentation: Outcome of Advanced Gastrointestinal Stromal Tumor (GIST) Patients Treated With Imatinib Mesylate: Four- Year Follow-Up of a Phase II Randomized Trial. Presentation Poster (pdf) Abstract (doc)